Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling
Kylie M. Quinn, … , Alan Aderem, Robert A. Seder
Kylie M. Quinn, … , Alan Aderem, Robert A. Seder
Published February 2, 2015
Citation Information: J Clin Invest. 2015;125(3):1129-1146. https://doi.org/10.1172/JCI78280.
View: Text | PDF
Research Article Article has an altmetric score of 61

Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling

  • Text
  • PDF
Abstract

Recombinant adenoviral vectors (rAds) are lead vaccine candidates for protection against a variety of pathogens, including Ebola, HIV, tuberculosis, and malaria, due to their ability to potently induce T cell immunity in humans. However, the ability to induce protective cellular immunity varies among rAds. Here, we assessed the mechanisms that control the potency of CD8 T cell responses in murine models following vaccination with human-, chimpanzee-, and simian-derived rAds encoding SIV-Gag antigen (Ag). After rAd vaccination, we quantified Ag expression and performed expression profiling of innate immune response genes in the draining lymph node. Human-derived rAd5 and chimpanzee-derived chAd3 were the most potent rAds and induced high and persistent Ag expression with low innate gene activation, while less potent rAds induced less Ag expression and robustly induced innate immunity genes that were primarily associated with IFN signaling. Abrogation of type I IFN or stimulator of IFN genes (STING) signaling increased Ag expression and accelerated CD8 T cell response kinetics but did not alter memory responses or protection. These findings reveal that the magnitude of rAd-induced memory CD8 T cell immune responses correlates with Ag expression but is independent of IFN and STING and provide criteria for optimizing protective CD8 T cell immunity with rAd vaccines.

Authors

Kylie M. Quinn, Daniel E. Zak, Andreia Costa, Ayako Yamamoto, Kathrin Kastenmuller, Brenna J. Hill, Geoffrey M. Lynn, Patricia A. Darrah, Ross W.B. Lindsay, Lingshu Wang, Cheng Cheng, Alfredo Nicosia, Antonella Folgori, Stefano Colloca, Riccardo Cortese, Emma Gostick, David A. Price, Jason G.D. Gall, Mario Roederer, Alan Aderem, Robert A. Seder

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 Total
Citations: 4 6 4 11 13 10 2 3 7 12 5 77
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2021 (13)

Title and authors Publication Year
Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection
O Flynn, K Dillane, JS Lanza, JM Marshall, J Jin, SE Silk, SJ Draper, AC Moore
Human vaccines 2021
Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
LJ Kerstetter, S Buckley, CM Bliss, L Coughlan
Frontiers in immunology 2021
Codon Usage and Adenovirus Fitness: Implications for Vaccine Development
J Giménez-Roig, E Núñez-Manchón, R Alemany, E Villanueva, C Fillat
Frontiers in microbiology 2021
MAIT cell activation augments adenovirus vector vaccine immunogenicity
NM Provine, A Amini, LC Garner, AJ Spencer, C Dold, C Hutchings, LS Reyes, ME FitzPatrick, S Chinnakannan, B Oguti, M Raymond, M Ulaszewska, F Troise, H Sharpe, SB Morgan, TS Hinks, T Lambe, S Capone, A Folgori, E Barnes, CS Rollier, AJ Pollard, P Klenerman
Science 2021
Delivery of Anti-IFNAR1 shRNA to Hepatic Cells Decreases IFNAR1 Gene Expression and Improves Adenoviral Transduction and Transgene Expression
J Guerrero-Rodríguez, A Cárdenas-Vargas, G Gutierrez-Silerio, A Sobrevilla-Navarro, B Bastidas-Ramírez, L Hernández-Ortega, C Gurrola-Díaz, L Gasca-Lozano, J Armendáriz-Borunda, A Salazar-Montes
Molecular Biotechnology 2021
A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
MJ Sklar, S Maiolatesi, N Patterson, M Sedegah, K Limbach, N Teneza-Mora, I Chuang, KM Hollis-Perry, JG Banania, I Guzman, H Ganeshan, S Reyes, MR Hollingdale, M Wong, A Lindstrom, A Reyes, Y Alcorta, L Garver, K Bankard, A Belmonte, M Belmonte, J Huang, K Gowda, S Inoue, R Velasco, E Bergmann-Leitner, J Hutter, T Lee, N Adams, S Chaudhury, D Hunt, C Tamminga, E Berrie, D Bellamy, M Bittaye, K Ewer, C Diggs, LA Soisson, A Lawrie, A Hill, TL Richie, E Villasante, JE Epstein, CA Duplessis, SR Walsh
PloS one 2021
Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity
S Sanchez, N Palacio, T Dangi, T Ciucci, P Penaloza-MacMaster
Science Immunology 2021
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
S Capone, A Raggioli, M Gentile, S Battella, A Lahm, A Sommella, AM Contino, RA Urbanowicz, R Scala, F Barra, A Leuzzi, E Lilli, G Miselli, A Noto, M Ferraiuolo, F Talotta, T Tsoleridis, C Castilletti, G Matusali, F Colavita, D Lapa, S Meschi, M Capobianchi, M Soriani, A Folgori, JK Ball, S Colloca, A Vitelli
Molecular Therapy 2021
Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections
A Elkashif, M Alhashimi, E Sayedahmed, S Sambhara, S Mittal
IBMS BoneKEy 2021
A New Look at Vaccine Strategies Against PPRV Focused on Adenoviral Candidates
J Rojas, N Sevilla, V Martín
Frontiers in Veterinary Science 2021
Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines
S Farhang-Sardroodi, C Korosec, S Gholami, M Craig, I Moyles, M Ghaemi, H Ooi, J Heffernan
Human vaccines 2021
Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses
J Powers, N Haese, M Denton, T Ando, C Kreklywich, K Bonin, C Streblow, N Kreklywich, P Smith, R Broeckel, V DeFilippis, T Morrison, M Heise, D Streblow, R Wang
PLoS neglected tropical diseases 2021
Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity
Sanchez S, Palacio N, Dangi T, Ciucci T, Penaloza-MacMaster P
2021

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 8 news outlets
Posted by 1 X users
108 readers on Mendeley
See more details